Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 85, Issue 10, Pages 2228-2234Publisher
WILEY
DOI: 10.1111/bcp.14057
Keywords
clinical pharmacology; methotrexate; pharmacodynamics; pharmacokinetics; prescribing; rheumatoid arthritis
Categories
Ask authors/readers for more resources
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available